Bio-Rad Laboratories, Inc. Share Price NYSE
Stocks
BIO.B
US0905721082
Medical Equipment, Supplies & Distribution
|
Market Closed -
NYSE
01:40:00 21/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 365.08 USD | +8.33% |
|
+8.33% | +17.50% |
| 07/08 | RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating | MT |
| 05/08 | RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating | MT |
| Market Cap | 1.03TCr 883.39Cr 827.75Cr 756.1Cr 1.43TCr 98TCr 1.44TCr 9.76TCr 3.8TCr 50TCr 3.87TCr 3.79TCr 1,64200Cr | P/E 2026 * |
46.9x | P/E 2027 * | 45.9x |
|---|---|---|---|---|---|
| Enterprise Value | 956.01Cr 819.21Cr 767.61Cr 701.17Cr 1.32TCr 91TCr 1.34TCr 9.05TCr 3.52TCr 46TCr 3.59TCr 3.51TCr 1,52300Cr | EV / Sales 2026 * |
3.72x | EV / Sales 2027 * | 3.55x |
| Free-Float |
60.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Bio-Rad Laboratories, Inc.
| 1 day | +8.33% | ||
| 1 week | +8.33% | ||
| Current month | +18.01% | ||
| 1 month | +18.01% | ||
| 3 months | +36.51% | ||
| 6 months | +35.78% | ||
| Current year | +17.50% |
| 1 week | 365.08 |  | 365.08 |
| 1 month | 337 | | 365.08 |
| Current year | 244.54 | | 365.08 |
| 1 year | 244.54 | | 365.08 |
| 3 years | 0 | | 373.78 |
| 5 years | 0 | | 818.6 |
| 10 years | 0 | | 818.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CEO | Chief Executive Officer | 76 | 01/01/2003 |
| President | 61 | 09/09/2024 | |
Roop Lakkaraju
DFI | Director of Finance/CFO | 55 | 15/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Norman Schwartz
CHM | Chairman | 76 | 01/01/2012 |
Jeffrey Edwards
BRD | Director/Board Member | 73 | 25/04/2017 |
Gregory Hinckley
BRD | Director/Board Member | 79 | 25/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +8.33% | +8.33% | - | - | 1.01TCr | |
| -0.46% | +3.06% | -11.94% | +11.44% | 20TCr | |
| -1.89% | -1.03% | -0.98% | +10.89% | 12TCr | |
| +1.33% | +3.77% | +13.79% | +82.78% | 6.18TCr | |
| -0.28% | -1.89% | +29.47% | +56.43% | 5.23TCr | |
| -0.50% | +4.98% | -2.50% | -32.22% | 5.2TCr | |
| -2.09% | -0.49% | +17.38% | -11.51% | 3.44TCr | |
| +2.71% | +4.45% | - | - | 3.04TCr | |
| -1.37% | +0.55% | +40.97% | -11.49% | 2.49TCr | |
| -0.04% | +4.98% | -1.93% | +20.84% | 2.41TCr | |
| Average | +0.58% | +1.12% | +10.53% | +15.89% | 6.67TCr | |
| Weighted average by Cap. | -0.35% | +1.39% | +2.29% | +17.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 257.33Cr 220.51Cr 206.62Cr 188.73Cr 356.19Cr 25TCr 359.7Cr 2.44TCr 948.78Cr 12TCr 966.23Cr 945.18Cr 41TCr | 263.35Cr 225.66Cr 211.45Cr 193.15Cr 364.52Cr 25TCr 368.11Cr 2.49TCr 970.97Cr 13TCr 988.82Cr 967.28Cr 42TCr |
| Net income | 22Cr 19Cr 18Cr 17Cr 31Cr 2.15TCr 31Cr 213.1Cr 83Cr 1.08TCr 84Cr 83Cr 3.58TCr | 23Cr 20Cr 18Cr 17Cr 32Cr 2.19TCr 32Cr 217.83Cr 85Cr 1.11TCr 86Cr 84Cr 3.66TCr |
| Net Debt | -75Cr -64Cr -60Cr -55Cr -103.68Cr -7.14TCr -104.7Cr -709.4Cr -276.16Cr -3.6TCr -281.24Cr -275.11Cr -12TCr | -97Cr -83Cr -78Cr -71Cr -133.63Cr -9.2TCr -134.95Cr -914.35Cr -355.95Cr -4.64TCr -362.5Cr -354.6Cr -15TCr |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIO Stock
- BIO.B Stock
Select your edition
All financial news and data tailored to specific country editions
